Unsupervised machine learning algorithms identify expected haemorrhage relationships but define unexplained coagulation profiles mapping to thrombotic phenotypes in hereditary haemorrhagic telangiectasia

Ghazel Mukhtar, Claire L Shovlin, Ghazel Mukhtar, Claire L Shovlin

Abstract

Hereditary haemorrhagic telangiectasia (HHT) can result in challenging anaemia and thrombosis phenotypes. Clinical presentations of HHT vary for relatives with identical casual mutations, suggesting other factors may modify severity. To examine objectively, we developed unsupervised machine learning algorithms to test whether haematological data at presentation could be categorised into sub-groupings and fitted to known biological factors. With ethical approval, we examined 10 complete blood count (CBC) variables, four iron index variables, four coagulation variables and eight iron/coagulation indices combined from 336 genotyped HHT patients (40% male, 60% female, 86.5% not using iron supplementation) at a single centre. T-SNE unsupervised, dimension reduction, machine learning algorithms assigned each high-dimensional datapoint to a location in a two-dimensional plane. k-Means clustering algorithms grouped into profiles, enabling visualisation and inter-profile comparisons of patients' clinical and genetic features. The unsupervised machine learning algorithms using t-SNE and k-Means identified two distinct CBC profiles, two iron profiles, four clotting profiles and three combined profiles. Validating the methodology, profiles for CBC or iron indices fitted expected patterns for haemorrhage. Distinct coagulation profiles displayed no association with age, sex, C-reactive protein, pulmonary arteriovenous malformations (AVMs), ENG/ACVRL1 genotype or epistaxis severity. The most distinct profiles were from t-SNE/k-Means analyses of combined iron-coagulation indices and mapped to three risk states - for venous thromboembolism in HHT; for ischaemic stroke attributed to paradoxical emboli through pulmonary AVMs in HHT; and for cerebral abscess attributed to odontogenic bacteremias in immunocompetent HHT patients with right-to-left shunting through pulmonary AVMs. In conclusion, unsupervised machine learning algorithms categorise HHT haematological indices into distinct, clinically relevant profiles which are independent of age, sex or HHT genotype. Further evaluation may inform prophylaxis and management for HHT patients' haemorrhagic and thrombotic phenotypes.

Keywords: anaemia; genetic disorders; haemorrhage; high‐dimensional data; t‐SNE.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Complete blood count indices. Two‐dimensional scatter plot of the t‐SNE embeddings and k‐Means clusters for CBC indices (n = 336). Each datapoint represents a patient. k‐Means clusters are displayed by colour. Distances between datapoints representative of similarity.
FIGURE 2
FIGURE 2
Iron indices. Two‐dimensional scatter plot of the t‐SNE embeddings and k‐Means clusters for CBC indices (n = 218). Each datapoint represents a patient. k‐Means clusters are displayed by colour. Distances between datapoints representative of similarity.
FIGURE 3
FIGURE 3
Clotting indices. Two‐dimensional scatter plot of the t‐SNE embeddings and k‐Means clusters for CBC indices (n = 309). Each datapoint represents a patient. k‐Means clusters are displayed by colour. Distances between datapoints representative of similarity.
FIGURE 4
FIGURE 4
Combined iron and clotting indices. Two‐dimensional scatter plot of the t‐SNE embeddings and k‐Means clusters for iron and clotting indices (n = 196). Each datapoint represents a patient. k‐Means clusters are displayed by colour.

References

    1. European Reference Network for Rare Vascular Disease (VASCERN): Hereditary haemorrhagic telangiectasia. Available from: . Accessed 23 Oct 2022.
    1. Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. New Engl J Med. 1995;333:918–24.
    1. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010;24:203–19
    1. Hoag J, Terry P, Mitchell S, Reh D, Merlo C. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010;120:838–43
    1. Shovlin CL, Simeoni I, Downes K, Frazer ZC, Megy K, Bernabeu‐Herrero ME, et al. Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. Blood. 2020;136(17):1907–18. 10.1182/blood.2019004560
    1. Bernabeu C, Bayrak‐Toydemir P, McDonald J, Letarte M. Potential second‐hits in hereditary hemorrhagic telangiectasia. J Clin Med. 2020;9:3571.
    1. Hetts SW, Shieh JT, Ohliger MA, Conrad MB. Hereditary hemorrhagic telangiectasia: the convergence of genotype, phenotype, and imaging in modern diagnosis and management of a multisystem disease. Radiology. 2021;300:17–30.
    1. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu‐Osler‐Weber syndrome). Am J Med Genet. 2000;91:66–7
    1. Anderson E, Sharma L, Alsafi A, Shovlin CL. Pulmonary arteriovenous malformations may be the only clinical criterion present in genetically confirmed hereditary haemorrhagic telangiectasia. Thorax. 2022;77(6):628–30
    1. Cottin V, Plauchu H, Bayle J‐Y, Barthelet M, Revel D, Cordier JF. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med. 2004;169:994–100
    1. Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, et al. Genotype‐phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet. 2006;43(4):371–7.
    1. European Association for the Study of the Liver . EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.
    1. Eker OF, Boccardi E, Sure U, Patel MC, Alicante S, Alsafi A, et al. European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis. 2020;15(1):165.
    1. Topiwala KK, Patel SD, Pervez M, Shovlin CL, Alberts MJ. Ischemic stroke in patients with pulmonary arteriovenous fistulas. Stroke. 2021;52(7):e311–5
    1. Topiwala KK, Patel SD, Saver JL, Streib CD, Shovlin CL. Ischemic stroke and pulmonary arteriovenous malformations: a review. Neurology. 2022;98(5):188–98
    1. Shovlin CL, Chamali B, Santhirapala V, Livesey JA, Angus G, Manning R, et al. Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets. PLoS One. 2014;9(2):e88812. 10.1371/journal.pone.0088812
    1. Boother EJ, Brownlow S, Tighe HC, Bamford KB, Jackson JE, Shovlin CL. Cerebral abscess associated with odontogenic bacteremias, hypoxemia, and iron loading in immunocompetent patients with right‐to‐left shunting through pulmonary arteriovenous malformations. Clin Infect Dis. 2017;65(4):595–603. 10.1093/cid/cix373
    1. Dupuis‐Girod S, Giraud S, Decullier E, Lesca G, Cottin V, Faure F, et al. Hemorrhagic hereditary telangiectasia (Rendu‐Osler disease) and infectious diseases: an underestimated association. Clin Infect Dis. 2007;44(6):841–5.
    1. Shovlin CL, Condliffe R, Donaldson JW, Kiely DG, Wort SJ, British Thoracic Society . British Thoracic Society Clinical statement on pulmonary arteriovenous malformations. Thorax. 2017;72(12):1154–63.
    1. Müller‐Hülsbeck S, Marques L, Maleux G, Osuga K, Pelage JP, Wohlgemuth WA, et al. CIRSE standards of practice on diagnosis and treatment of pulmonary arteriovenous malformations. Cardiovasc Intervent Radiol. 2020;43(3):353–61
    1. Buscarini E, Leandro G, Conte D, Danesino C, Daina E, Manfredi G, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci. 2011;56(7):2166–78.
    1. Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang‐Robertson K, Buscarini E, et al. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020;173(12):989–1001. 10.7326/M20-1443
    1. Shovlin CL, Buscarini E, Sabbà C, Mager HJ, Kjeldsen AD, Pagella F, et al. . The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care. Eur J Med Genet. 2022;65(1):104370. 10.1016/j.ejmg.2021.104370
    1. Finnamore H, Le Couteur J, Hickson M, Busbridge M, Whelan K, Shovlin CL. Hemorrhage‐adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. PLoS One. 2013;8(10):e76516.
    1. Pasricha S‐R, Tye‐Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2020;397:233–48
    1. Thielemans L, Layton DM, Shovlin CL. Low serum haptoglobin and blood films suggest intravascular hemolysis contributes to severe anemia in hereditary hemorrhagic telangiectasia. Haematologica. 2019;104:e127–30.
    1. Livesey JA, Manning RA, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax. 2012;67(4):328–33.
    1. Woods HF, Youdim MBH, Boullin D, Callender S. Monoamine metabolism and platelet function in iron‐deficiency anaemia. In: Iron metabolism. CIBA Foundation Symposium 51 (new series). Amsterdam: Elsevier; 1977, 227–48
    1. Shovlin CL, Hughes JM, Tuddenham EG, Temperley I, Perembelon YF, Scott J, et al. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nat Genet. 1994;6(2):205–9.
    1. Shovlin CL, Hughes JM, Scott J, Seidman CE, Seidman JG. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. 1997l;61(1):68–79.
    1. Sharma L, Almaghlouth F, Mckernan H, Springett J, Tighe HC, Genomics England Research Consortium , Shovlin CL. Iron deficiency responses and integrated compensations in patients according to hereditary haemorrhagic telangiectasia ACVRL1¸ ENG and SMAD4 genotypes. Haematologica. 2023. In Press.
    1. Joyce KE, Onabanjo E, Brownlow S, Nur F, Olupona K, Fakayode K, et al. Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non‐HHT deleterious DNA variation. Blood Adv. 2022;6(13):3956–69.
    1. Scikit‐learn. Sklearn.preprocessing.StandardScaler. Available from: . Accessed 24 May 2022.
    1. Dokmanic I, Parhizkar R, Ranieri J, Vetterli M. Euclidean distance matrices: essential theory, algorithms, and applications. IEEE Signal Processing Magazine. 2015;32(6):12–30.
    1. Scikit‐learn. sklearn.manifold.TSNE. Available from: . Accessed 24 May 2022.
    1. Shahapure KR. Nicholas C. Cluster Quality Analysis Using Silhouette Score. – 2020 IEEE 7th International Conference on Data Science and Advanced Analytics (DSAA) 2020, 747–48.
    1. Mhadgut H, Galadima H, Tahhan HR. Thrombocytosis in iron deficiency anemia. Blood. 2018;132:4985.
    1. Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT, editors, Wintrobe's Clinical Haematology 12th Edition. Philadelphia: Jr. Wolters Kluwer; 2009.
    1. Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost. 2007;98(5):1031–9.
    1. Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med. 2013;368(9):876–8
    1. Shovlin CL, Millar CM, Droege F, Kjeldsen A, Manfredi G, Suppressa P, et al. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):210
    1. Gaetani E, Agostini F, Giarretta I, Porfidia A, Di Martino L, Gasbarrini A, et al. Antithrombotic therapy in hereditary hemorrhagic telangiectasia: real‐world data from the gemelli hospital HHT registry. J Clin Med. 2020;9(6):1699.
    1. Zhang E, Virk ZM, Rodriguez‐Lopez J, Al‐Samkari H. Anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia: a scoping review. Thromb Res. 2023;226:150–55.
    1. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population‐based study of prevalence and mortality in Danish patients. J Intern Med. 1999;245(1):31–9
    1. Shovlin CL, Gilson C, Busbridge M, Patel D, Shi C, Dina R, et al. Can iron treatments aggravate epistaxis in some patients with hereditary hemorrhagic telangiectasia? Laryngoscope. 2016;126(11):2468–74.
    1. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice‐daily doses in iron‐depleted young women. Blood. 2015;126(17):1981–89
    1. Shovlin CL, Patel T, Jackson JE. Embolisation of PAVMs reported to improve nosebleeds by a subgroup of patients with hereditary haemorrhagic telangiectasia. ERJ Open Res. 2016;2:00035–2016.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe